Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 2:50 PM
Ignite Modification Date:
2025-12-24 @ 2:50 PM
NCT ID:
NCT06900959
Eligibility Criteria:
Inclusion Criteria:
* Males or females aged between 18 and 80 years;
* Presence of a neurological disorder, specifically the following conditions will be considered: MS, ALS, PD, AD, Dementias, TBI, neurosurgical interventions, stroke, fibromyalgia, epilepsy, headache, migraine, with at least one of the following symptoms: pain, neuropathic pain, neuralgias, depression, anxiety, apathy, fatigue, cognitive decline, aphasia, functional motor disorders (FMD), neuromuscular tone alterations, hyposthenia, involvement of multiple cognitive functions (including decision-making, problem-solving, learning, memory, executive functions, social and emotional cognition);
* Patients must be able to follow the protocol instructions for the duration of the study;
* Be able to understand the purposes and risks of the study;
* Be able to understand and provide written informed consent to the study.
Exclusion Criteria:
* Partial or total inability to understand or make decisions, inability to provide written informed consent for the study;
* Patients with a history or presence of any unstable medical condition, such as neoplasms or infections;
* Women with a positive pregnancy test at baseline or planning to become pregnant. Women who are breastfeeding or have given birth within the last three months prior to the start of the study;
* Use of medications that increase the risk of seizures (e.g., Fampridine, 4-aminopyridine);
* Concurrent use of medications that may alter synaptic transmission and plasticity (L-dopa, antiepileptics);
* In the case of using NIBS techniques, subjects should not have any contraindications specific to this method (for further details, see the "Methods" and the "Stimulation Assessment Questionnaire" attached to this proposal).
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
80 Years
Study:
NCT06900959
Study Brief:
Protocol Section:
NCT06900959